Walgreens Tops CVS's Offer for Longs Drug Stores (LDG)
More News related to CVS
- CVS Caremark Applauds FTC's Leadership on Follow-on Biologics
- Black Friday Shopping Event Starts Early at CVS/pharmacy
- Quarterly Data Confirms Hedge Funds Exited Stocks In A Big Way
- CVS.com Named Best Consumer Health Product Internet Site
- Loeb's Third Point 13F; Shows New Stakes in BUD, C, CVS, MER, WEN, UST, Sells Out of MA
More News related to LDG
- CVS Caremark Successfully Completes Tender Offer for Longs Shares
- CVS Caremark (CVS) Reports Tender Offer for Longs (LDG) at $71.50/Share Has Been Successful
- CVS Caremark Reports Successful Tender Offer for Longs Drug Stores Shares
- CVS Caremark Extends Tender Offer for Longs Drug Stores Shares by One Day
- Notable Mergers and Acquisitions of the Day 10/16: CVS/LDG, BA, ESIO/ZIGO
More News related to WAG
- Walgreens Celebrates the Grand Opening of Its Flagship Store in Times Square
- Walgreens Offers Help Sorting Through Changes to Medicare Part D Plans
- Walgreens MedMonitor(R) Complete Reduces Total Health Care Costs with a 3.7 and 7.8 ROI
- Take Care Health Systems Celebrates National Nurse Practitioner Week
- Walgreens Specialty Pharmacy Awarded ACHC Accreditation
More News related to Mergers and Acquisitions
- Barr (BRL) Shareholders Approval Proposed Acquisition of Teva (TEVA)
- Epicor Software (EPIQ) Comments on the Termination of Elliott Associates' Tender Offer
- Mediware (MEDW) Acquires Assets of Hann's On Software for $3.5M; Purchase Adds 320 Pharmacy Facilities to Operations
- Iowa Telecommunications (IWA) to Acquire Sherburne Tele Systems for $80.6M
- Citigroup (C) Looking At Sale Options As Stock Plunges
Late Friday, Walgreens (NYSE: WAG) announced an offer to acquire Longs Drug Stores Corporation (NYSE: LDG) for $75 per share in cash. Walgreens' offer represents a $3.50 per share premium over the proposed acquisition of Longs by CVS/Caremark (NYSE: CVS) announced on Aug. 12.
Longs Drug Stores, which agreed to the CVS offer, has yet to respond to the new Walgreens offer.
Large shareholders of Longs Drug Stores, including Bill Ackman of Pershing Square Capital and Advisory Research, have publicly stated their opposition to the CVS/Longs merger, saying the bidding process was flawed and the offer was too low.
Related Categories
Hot ListMergers and Acquisitions
Stocks Mentioned
-0.41
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
